TiumBio Statistics
Total Valuation
TiumBio has a market cap or net worth of KRW 111.13 billion. The enterprise value is 128.86 billion.
Market Cap | 111.13B |
Enterprise Value | 128.86B |
Important Dates
The next estimated earnings date is Friday, March 21, 2025.
Earnings Date | Mar 21, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
TiumBio has 26.03 million shares outstanding. The number of shares has increased by 5.05% in one year.
Current Share Class | n/a |
Shares Outstanding | 26.03M |
Shares Change (YoY) | +5.05% |
Shares Change (QoQ) | +3.68% |
Owned by Insiders (%) | 33.12% |
Owned by Institutions (%) | 0.36% |
Float | 12.26M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 14.17 |
PB Ratio | 2.52 |
P/TBV Ratio | 2.54 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -6.33 |
EV / Sales | 16.80 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -6.24 |
Financial Position
The company has a current ratio of 2.41, with a Debt / Equity ratio of 0.48.
Current Ratio | 2.41 |
Quick Ratio | 2.02 |
Debt / Equity | 0.48 |
Debt / EBITDA | n/a |
Debt / FCF | -1.30 |
Interest Coverage | -4.20 |
Financial Efficiency
Return on equity (ROE) is -48.07% and return on invested capital (ROIC) is -14.35%.
Return on Equity (ROE) | -48.07% |
Return on Assets (ROA) | -12.30% |
Return on Capital (ROIC) | -14.35% |
Revenue Per Employee | 182.64M |
Profits Per Employee | -484.58M |
Employee Count | 42 |
Asset Turnover | 0.08 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.60% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -49.60% |
50-Day Moving Average | 5,017.40 |
200-Day Moving Average | 6,329.15 |
Relative Strength Index (RSI) | 43.94 |
Average Volume (20 Days) | 80,060 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TiumBio had revenue of KRW 7.67 billion and -20.35 billion in losses. Loss per share was -799.30.
Revenue | 7.67B |
Gross Profit | 7.67B |
Operating Income | -18.08B |
Pretax Income | -22.39B |
Net Income | -20.35B |
EBITDA | -14.96B |
EBIT | -18.08B |
Loss Per Share | -799.30 |
Balance Sheet
The company has 20.88 billion in cash and 26.93 billion in debt, giving a net cash position of -6.05 billion or -232.46 per share.
Cash & Cash Equivalents | 20.88B |
Total Debt | 26.93B |
Net Cash | -6.05B |
Net Cash Per Share | -232.46 |
Equity (Book Value) | 55.74B |
Book Value Per Share | 1,693.14 |
Working Capital | 15.68B |
Cash Flow
In the last 12 months, operating cash flow was -17.35 billion and capital expenditures -3.31 billion, giving a free cash flow of -20.65 billion.
Operating Cash Flow | -17.35B |
Capital Expenditures | -3.31B |
Free Cash Flow | -20.65B |
FCF Per Share | -793.54 |
Margins
Gross margin is 100.00%, with operating and profit margins of -235.73% and -265.33%.
Gross Margin | 100.00% |
Operating Margin | -235.73% |
Pretax Margin | -291.90% |
Profit Margin | -265.33% |
EBITDA Margin | -195.03% |
EBIT Margin | -235.73% |
FCF Margin | n/a |
Dividends & Yields
TiumBio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -5.05% |
Shareholder Yield | -5.05% |
Earnings Yield | -18.72% |
FCF Yield | -18.58% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
TiumBio has an Altman Z-Score of 0.31. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 0.31 |
Piotroski F-Score | n/a |